Unmet Needs in LDL-C Lowering: When Statins Won’t Do!

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

(2016) Marc S. Sabatine et al.   AMERICAN HEART JOURNAL

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

(2016) Michel Farnier et al.   ATHEROSCLEROSIS

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry)

(2015) Sarah A. Spinler et al.   AMERICAN JOURNAL OF CARDIOLOGY

Frequency of High-Risk Patients Not Receiving High-Potency Statin (from a Large Managed Care Database)

(2015) Fatima Rodriguez et al.   AMERICAN JOURNAL OF CARDIOLOGY

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity

(2015) Annalisa Bonifacio et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance

(2015) Dirk J. Blom et al.   CIRCULATION RESEARCH

Statins and diabetes risk

(2015) Jennifer G. Robinson   CURRENT OPINION IN LIPIDOLOGY

Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia

(2015) Matthew K. Ito et al.   DRUGS

Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease

(2015) Bo Kobberø Lauridsen et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus

(2015) Joost Besseling et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

(2015) Harold Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease

(2015) Rashmi Thapa et al.   Journal of Clinical Lipidology

Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials

(2015) Raju Panta et al.   Journal of Clinical Lipidology

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015)   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT

(2015) John A. Jarcho et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic

(2014) Fotios Barkas et al.   ANGIOLOGY

Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia

(2014) John Skoumas et al.   ATHEROSCLEROSIS

Novel Therapies Focused on the High-Density Lipoprotein Particle

(2014) Julian C. van Capelleveen et al.   CIRCULATION RESEARCH

Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

(2014) Jennifer G. Robinson et al.   CLINICAL CARDIOLOGY

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

(2014) Barbara Sjouke et al.   EUROPEAN HEART JOURNAL

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Mendelian randomization studies in coronary artery disease

(2014) H. Jansen et al.   EUROPEAN HEART JOURNAL

Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort

(2014) Maryam Kavousi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

(2014) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

An assessment by the Statin Muscle Safety Task Force: 2014 update

(2014) Robert S. Rosenson et al.   Journal of Clinical Lipidology

An assessment by the Statin Diabetes Safety Task Force: 2014 update

(2014) Kevin C. Maki et al.   Journal of Clinical Lipidology

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Severe Hypercholesterolemia Phenotype

(2014) Allan D. Sniderman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Contrasting Cholesterol Management Guidelines for Adults with CKD

(2014) L. D. Colantonio et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Lipid lowering with PCSK9 inhibitors

(2014) Razvan T. Dadu et al.   Nature Reviews Cardiology

Resistance and intolerance to statins

(2014) Ž. Reiner   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Discontinuation of Statins in Routine Care Settings

(2013) Huabing Zhang et al.   ANNALS OF INTERNAL MEDICINE

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update

(2013) G.B. John Mancini et al.   CANADIAN JOURNAL OF CARDIOLOGY

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

(2013) David C. Goff et al.   CIRCULATION

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy

(2013) Raghu Vishwanath et al.   Journal of Clinical Lipidology

Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management

(2013) Jooho Lee et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

(2013) Gregory S. Thomas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

(2013) Kevin Fitzgerald et al.   LANCET

Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia

(2013) Sony Tuteja et al.   PHARMACOTHERAPY

Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis

(2012) Catherine Buettner et al.   AMERICAN JOURNAL OF MEDICINE

Statins and Risk of New-Onset Diabetes Mellitus

(2012) Ravi V. Shah et al.   CIRCULATION

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

(2012) Evan A. Stein et al.   CIRCULATION

Effect of Statins on Skeletal Muscle Function

(2012) Beth A. Parker et al.   CIRCULATION

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users

(2012) Jerome D. Cohen et al.   Journal of Clinical Lipidology

Lomitapide for homozygous familial hypercholesterolaemia

(2012) Frederick J Raal   LANCET

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia

(2012) Terry A. Jacobson   MAYO CLINIC PROCEEDINGS

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

(2012) Mary P. McGowan et al.   PLoS One

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol

(2011) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and risk factors of muscle complications secondary to statins

(2011) Khalid El-Salem et al.   MUSCLE & NERVE

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis

(2010) Devin M Mann et al.   ANNALS OF PHARMACOTHERAPY

Cardiovascular Risk-Estimation Systems in Primary Prevention

(2010) Marie Therese Cooney et al.   CIRCULATION

Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice

(2010) J. K. Kruit et al.   DIABETOLOGIA

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statin Adverse Effects

(2009) Beatrice A Golomb et al.   American Journal of Cardiovascular Drugs

Continuation of Statin Treatment and All-Cause Mortality

(2009) Varda Shalev et al.   ARCHIVES OF INTERNAL MEDICINE

Low- and High-Density Lipoproteins Modulate Function, Apoptosis, and Proliferation of Primary Human and Murine Pancreatic β-Cells

(2009) Sabine Rütti et al.   ENDOCRINOLOGY

Combined therapy in the treatment of dyslipidemia

(2009) Željko Reiner   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk

(2009) Marie Therese Cooney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

General Cardiovascular Risk Profile for Use in Primary Care

(2008) Ralph B. D’Agostino et al.   CIRCULATION

Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in Israel

(2008) Gabriel Chodick et al.   CLINICAL THERAPEUTICS

Physicians’ Ability to Predict Patients’ Adherence to Antihypertensive Medication in Primary Care

(2008) Andreas ZELLER et al.   HYPERTENSION RESEARCH

Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments

(2008) Edward J. Mills et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study

(2008) Patrick Linsel-Nitschke et al.   PLoS One